Masahiro Natsuaki

Masahiro Natsuaki

Auto-generated profile, based on publicly available information

Masahiro Natsuaki

Department of Cardiovascular Medicine, Saga University , Saga 849-0937

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2024 in European Heart Journal
Verified
Journal Article
Open access
PDF file
HWHirotoshi Watanabe
Hirotoshi Watanabe
MNMasahiro Natsuaki
Masahiro Natsuaki
TMTakeshi Morimoto
Takeshi Morimoto
KYKo Yamamoto
Ko Yamamoto
YOYuki Obayashi
Yuki Obayashi
TKTakeshi Kimura
Takeshi Kimura
Background and Aims: There was no previous trial comparing aspirin monotherapy with a P2Y12 inhibitor monotherapy following short dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stents. Methods: In the STOPDAPT-3, patients with acute coronary syndrome or high bleeding risk (HBR) were randomly assigned to either 1-month dual antiplatelet therapy with aspirin and prasugrel followed by aspirin monotherapy (aspirin group) or 1-month prasugrel monotherapy followed by clopidogrel monotherapy (clopidogrel group). This secondary analysis compared aspirin monotherapy with clopidogrel monotherapy by the 30-day landmark analysis. The co-primary endpoints were the cardiovascular endpoint defined as a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, or ischaemic stroke and the bleeding endpoint defined as Bleeding Academic Research Consortium 3 or 5. Results: Of the 6002 assigned patients, 5833 patients (aspirin group: N = 2920 and clopidogrel group: N = 2913) were included in the 30-day landmark analysis. Median age was 73 (interquartile range 64–80) years, women 23.4%, acute coronary syndrome 74.6%, and high bleeding risk 54.1%. The assigned monotherapy was continued at 1 year in 87.5% and 87.2% in the aspirin and clopidogrel groups, respectively. The incidence rates beyond 30 days and up to 1 year were similar between the aspirin and clopidogrel groups for both cardiovascular endpoint [4.5 and 4.5 per 100 person-year, hazard ratio 1.00 (95% confidence interval .77–1.30), P = .97], and bleeding endpoint [2.0 and 1.9, hazard ratio 1.02 (95% confidence interval .69–1.52), P = .92]. Conclusions: Aspirin monotherapy compared with clopidogrel monotherapy was associated with similar cardiovascular and bleeding outcomes beyond 1 month and up to 1 year after percutaneous coronary intervention with drug-eluting stents (STOPDAPT-3 ClinicalTrials.gov number, NCT04609111).

1 May 2012 in The American Journal of Cardiology
Verified
Journal Article
Closed access
MNMasahiro Natsuaki
Masahiro Natsuaki
YNYoshihisa Nakagawa
Yoshihisa Nakagawa
TMTakeshi Morimoto
Takeshi Morimoto
KOKoh Ono
Koh Ono
SSSatoshi Shizuta
Satoshi Shizuta
TKTakeshi Kimura
Takeshi Kimura

1 March 2021 in The American Journal of Cardiology
Verified
Journal Article
Closed access
KYKo Yamamoto
Ko Yamamoto
MNMasahiro Natsuaki
Masahiro Natsuaki
TMTakeshi Morimoto
Takeshi Morimoto
HSHiroki Shiomi
Hiroki Shiomi
YMYukiko Matsumura-Nakano
Yukiko Matsumura-Nakano
TKTakeshi Kimura
Takeshi Kimura

28 February 2012 in Cardiovascular Intervention and Therapeutics
Verified
Journal Article
Closed access
PDF file
MNMasahiro Natsuaki
Masahiro Natsuaki
TMTakeshi Morimoto
Takeshi Morimoto
YFYutaka Furukawa
Yutaka Furukawa
YNYoshihisa Nakagawa
Yoshihisa Nakagawa
KKKazushige Kadota
Kazushige Kadota
TKTakeshi Kimura
Takeshi Kimura

16 October 2020 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
KYKo Yamamoto
Ko Yamamoto
HSHiroki Shiomi
Hiroki Shiomi
TMTakeshi Morimoto
Takeshi Morimoto
YTYasuaki Takeji
Yasuaki Takeji
YYYusuke Yoshikawa
Yusuke Yoshikawa
TKTakeshi Kimura
Takeshi Kimura

7 August 2019 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
HSHiroki Shiomi
Hiroki Shiomi
TMTakeshi Morimoto
Takeshi Morimoto
YFYutaka Furukawa
Yutaka Furukawa
YNYoshihisa Nakagawa
Yoshihisa Nakagawa
KAKenji Ando
Kenji Ando
TIthe CREDO-Kyoto PCI/CABG registry/cohort-2 investigators
the CREDO-Kyoto PCI/CABG registry/cohort-2 investigators